Athersys Reports Second Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Athersys (ATHX) Misses Q2 EPS by 2c
August 10, 2020 4:01 PM EDTAthersys (NASDAQ: ATHX) reported Q2 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $1.06 million.
Highlights of the second quarter of 2020 and recent events include:
Initiated and advanced enrollment in the Phase 2/3 COVID-19 induced acute respiratory distress syndrome (ARDS) clinical trial (the MACOVIA study) and currently evaluating the safety, tolerability and dose levels of MultiStem® cell therapy in this indication;Continued interactions with the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential collaboration;HEALIOS... More